10x Genomics, Inc. is an American biotechnology company founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. The company designs and manufactures advanced gene sequencing technologies used primarily in scientific research to enable a deeper understanding of biology and disease. It emerged from the founders’ vision to overcome limitations in existing genomics technologies by providing high-resolution insights at an unprecedented scale, especially at the single-cell level.

The company’s flagship product, the Chromium System, was launched in 2015. This innovative platform enabled researchers to analyze complex biological systems with single-cell resolution, driving significant advances in cellular biology. Over time, 10x Genomics has expanded its portfolio to include solutions for single-cell gene expression, immune profiling, epigenomics, genome sequencing, spatial transcriptomics, and in situ targeted gene expression profiling.

10x Genomics operates through a cycle of innovation, manufacturing, and commercialization, investing heavily in research and development—frequently dedicating over 40% of annual revenues to this effort. It produces integrated systems comprising instruments, consumables (such as proprietary microfluidic chips and reagents), and software that translate complex biological data into digital formats for deeper analysis.

Its products serve a wide range of customers including academic research labs, pharmaceutical and biotechnology companies, translational research centers, and clinical research organizations. The company has grown rapidly since its founding, with revenues climbing from $3.32 million in 2015 to over $600 million by 2023. It went public in September 2019, raising $390 million in its initial public offering.

Headquartered in Pleasanton, California, 10x Genomics continues to lead innovation in the genomics field, with a mission dedicated to fueling scientific discoveries and advancing human health through powerful and reliable tools.